Zobrazeno 1 - 10
of 28
pro vyhledávání: '"José Barrueco"'
Autor:
Jan P. van Meerbeeck, Derek Velema, Rasha Aboelhassan, Nick Pavlakis, Dean A. Fennell, Sanjay Popat, Giorgio V. Scagliotti, Takashi Nakano, Nicholas J. Vogelzang, Giovanni Luca Ceresoli, Anne S. Tsao, Marko Jakopović, Francisco Orlandi, MI-Young Kim, Martin Reck, Ute von Wangenheim, Anna K. Nowak, Jens Benn Sørensen, Kozo Kuribayashi, Silvia Novello, José Barrueco, Susana Cedres, Federica Grosso, Rabab Gaafar, Paul Taylor, Arnaud Scherpereel
Publikováno v:
The lancet respiratory medicine
Background Nintedanib targets VEGF receptors 1-3, PDGF receptors alpha and beta, FGF receptors 1-3, and Src and Abl kinases, which are all implicated in malignant pleural mesothelioma pathogenesis. Here, we report the final results of the phase 3 par
Autor:
Joachim von Pawel, Martin Reck, Hesham Aboshady, Igor Bondarenko, Maya Gottfried, Rolf Kaiser, Ying Cheng, José Barrueco, Jaafar Bennouna, Jean-Yves Douillard, Kostas Zarogoulidis, Anders Mellemgaard, Julia Hocke, Alexander Luft
Publikováno v:
Lung Cancer. 90:267-273
Objectives LUME-Lung 1 was a randomized, placebo-controlled, Phase III trial investigating nintedanib+docetaxel versus placebo+docetaxel in patients with advanced NSCLC progressing after first-line chemotherapy. Progression-free survival was signific
Autor:
David Planchard, Martin Reck, N. Morsli, Paul Taylor, Natasha B Leighl, José Barrueco, Federica Grosso, Silvia Novello, Sanjay Popat, Anna K. Nowak, Laurent Greillier, Giorgio V. Scagliotti, Thomas John, Mark A. Socinski, Nicola Steele, Jens Benn Sørensen, Arsene Bienvenu Loembe, Ute von Wangenheim
Purpose LUME-Meso is a phase II/III randomized, double-blind trial designed to assess efficacy and safety of nintedanib plus chemotherapy as first-line treatment of malignant pleural mesothelioma (MPM). Phase II results are reported here. Patients an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b3b67a7c511c65e68c6752a93e01b4b
http://hdl.handle.net/10044/1/55960
http://hdl.handle.net/10044/1/55960
Autor:
José Barrueco, John V. Heymach, Maya Gottfried, Birgit Gaschler-Markefski, Rolf Kaiser, Patricia Sikken, Claudia Nanette Gann, Anders Mellemgaard, Martin Reck, Silvia Novello, Nasser H. Hanna
Publikováno v:
Gaschler-Markefski, B, Sikken, P, Heymach, J V, Gottfried, M, Mellemgaard, A, Novello, S, Gann, C-N, Barrueco, J, Reck, M, Hanna, N H & Kaiser, R 2017, ' Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer ', E S M O Open, vol. 2, no. 1, e000102 . https://doi.org/10.1136/esmoopen-2016-000102
ESMO Open
ESMO Open
INTRODUCTION: No predictive clinical or genetic markers have been identified or validated for antiangiogenic agents in lung cancer. We aimed to identify a predictive clinical marker of benefit for nintedanib, an angiokinase inhibitor, using data from
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53bf9381dc3b4bba3f15bccc1002fcfa
https://curis.ku.dk/portal/da/publications/time-since-start-of-firstline-therapy-as-a-predictive-clinical-marker-for-nintedanib-in-patients-with-previously-treated-nonsmall-cell-lung-cancer(9ba7cd95-1500-45b8-92d8-c83b667e822d).html
https://curis.ku.dk/portal/da/publications/time-since-start-of-firstline-therapy-as-a-predictive-clinical-marker-for-nintedanib-in-patients-with-previously-treated-nonsmall-cell-lung-cancer(9ba7cd95-1500-45b8-92d8-c83b667e822d).html
Autor:
José Barrueco, Anne Tsao, J. Van Meerbeeck, N. Morsli, Sanjay Popat, Rabab Gaafar, Anna K. Nowak, G.V. Scagliotti, Nicholas J. Vogelzang, Takashi Nakano
Publikováno v:
Journal of Thoracic Oncology. 12:S2021-S2022
Publikováno v:
Investigative ophthalmologyvisual science. 56(13)
Purpose This study evaluated the effects of BIBF1120, a novel triple angiokinase inhibitor against pathological retinal neovascularization. Methods BIBF1120 effect on development of the normal retinal vasculature was evaluated in Sprague-Dawley rat p
Autor:
G.V. Scagliotti, José Barrueco, U. Von Wangenheim, Laurent Greillier, Martin Reck, David Planchard, Giovanni Luca Ceresoli, Julien Mazieres, Jens Benn Sørensen, Silvia Novello, Thomas John, Natasha B. Leighl, Mark A. Socinski, Federica Grosso, Anna K. Nowak, Brett G.M. Hughes, N. Morsli, Nick Pavlakis, Sanjay Popat, Nicola Steele
Publikováno v:
Annals of Oncology. 28:v569-v570
Autor:
David Planchard, Jens Benn Sørensen, Mark A. Socinski, Federica Grosso, Nicola Steele, Martin Reck, Anna K. Nowak, Arsene Bienvenu Loembe, Paul J. Taylor, Nick Pavlakis, Sanjay Popat, Ute von Wangenheim, José Barrueco, Giovanni Luca Ceresoli, Natasha B. Leighl, Julien Mazieres, Thomas John, Laurent Greillier, N. Morsli, Silvia Novello, Martha Mueller, Giorgio V. Scagliotti, Brett G.M. Hughes
Publikováno v:
Journal of Thoracic Oncology. 12:S329-S330
Autor:
MI-Young Kim, Anne Tsao, Silvia Novello, Nicholas J. Vogelzang, G.V. Scagliotti, R. Aboelhassan, Dean A. Fennell, Marko Jakopović, Rabab Gaafar, Federica Grosso, Arnaud Scherpereel, Giovanni Luca Ceresoli, Anna K. Nowak, Takashi Nakano, U. Von Wangenheim, J. Van Meerbeeck, Sanjay Popat, Paul Taylor, José Barrueco, Francisco Orlandi
Publikováno v:
Journal of Thoracic Oncology. 13:S186